Helen Torley has sold HALO and made no open-market buys since Nov 2020

Dr. Helen I. Torley, M.B. Ch.B., M.R.C.P. is the President and Chief Executive Officer of Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company focused on developing and commercializing novel oncology therapies and drug‑delivery solutions.( She joined Halozyme in January 2014 as president and CEO and also serves on its board of directors, bringing extensive commercial and operational experience in the biopharmaceutical industry.( Under her leadership, Halozyme has advanced technologies that enable subcutaneous delivery of medicines and has strengthened its position in oncology and drug‑delivery partnerships.(

Prior to Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer at Onyx Pharmaceuticals, where she led the successful U.S. launch of Kyprolis and built ex‑U.S. commercial capabilities, particularly in Europe.( She spent a decade at Amgen, most recently as Vice President and General Manager of the U.S. Bone Health and U.S. Nephrology business units, and previously held senior commercial and medical roles at Bristol‑Myers Squibb and Sandoz/Novartis.( A rheumatologist by training, she began her career in clinical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland.( Dr. Torley earned her Bachelor of Medicine and Bachelor of Surgery (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P.).( She has also been recognized as EY Entrepreneur Of The Year 2018 San Diego (Operational Excellence) and serves on the board of directors of Quest Diagnostics.(

Written by Perplexity from public sources.